Showing results (101-110 of 186) with videos related to
Sort By:
Pageof 19
Thrombosis and Haemostasis|April 28, 2017
Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL)Roberto Mario Santi, Manuela Ceccarelli, Elisa Bernocco, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 16, 2013
NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastasesGianpaolo Fogliatto, Laura Gianellini, Maria G Brasca, et al.Leukemia & Lymphoma|February 5, 2015
Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemiaAlessandra Tedeschi, Paola Picardi, Simone Ferrero, et al.Cancers|February 15, 2022
Treatment with Idelalisib in Patients with Relapsed or Refractory Follicular Lymphoma: The Observational Italian Multicenter FolIdela StudyBeatrice Casadei, Lisa Argnani, Alessandro Broccoli, et al.American Journal of Hematology|August 12, 2020
Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapiesMarzia Varettoni, Angela Ferrari, Anna M Frustaci, et al.British Journal of Cancer|September 27, 2017
Hepatitis C virus positive diffuse large B-cell lymphomas have distinct molecular features and lack BCL2 translocationsCarlo Visco, Jinfen Wang, Maria Chiara Tisi, et al.Bioorganic & Medicinal Chemistry|October 9, 2013
Discovery of NMS-E973 as novel, selective and potent inhibitor of heat shock protein 90 (Hsp90)Maria Gabriella Brasca, Sergio Mantegani, Nadia Amboldi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2022
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana LinfomiMichele Merli, Sara Rattotti, Michele Spina, et al.Cancer|March 21, 2014
Prevalence and clinical implications of cyclin D1 expression in diffuse large B-cell lymphoma (DLBCL) treated with immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium ProgramChi Young Ok, Zijun Y Xu-Monette, Alexandar Tzankov, et al.Blood|July 12, 2019
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 studyStefano Luminari, Michele Merli, Sara Rattotti, et al.Pageof 19